REGISTRATION INFO

This is a 1-day meeting and will provide 6 CE/CME credits.

Conference Registration Fee

Practicing Healthcare Professionals: $129

Register now >>

Non-Clinicians / Medical Office Support Staff / Industry Participants

In order to maintain the clinical nature of the conference, nonclinicians—including, but not limited to, office managers, billing specialists, receptionists, and administrative staff; guests, spouses, friends, and/or family members—may not attend PAINWeekEnd.

Please note: Discount room blocks are not available at this hotel. Please contact the hotel directly should you require accommodations.

Renaissance Tampa International Plaza Hotel
4200 Jim Walter Blvd.
Tampa, FL 33607

View hotel website >>

Get Directions using Google Maps

Faculty and courses are subject to change. Please refer to the online agenda below for the most recent course descriptions.

To view the agenda below, click on the + sign next to the day of the conference to expand the conference agenda. Click on the + signs within the agenda to view the course description, UAN number, and AANP pharmacology credits.

Schedule subject to change.

Saturday, June 27, 2020

  • REGISTRATION & EXHIBITS

    Coffee will be served.

  • He SAID, She SAID. What's the Deal with NSAIDs?

    Safety concerns, new warnings, and new formulations focused on harm reduction have led many providers to question NSAIDs place in therapy. NSAIDs have been a cornerstone of pain management of inflammatory, connective tissue, and autoimmune disorders for over a hundred years. A historical perspective is key to understanding the role of NSAIDs in pain management, and a therapeutic update on current evidence will aid providers in practical utilization. The safety of NSAIDs will be reviewed and compared to risks of other medications including opioids. New FDA warnings on cardiovascular risk of NSAIDs will be placed into context and examples of clinical decision-making provided. In addition, new formulations of NSAIDs will be discussed including IV NSAIDs, topical NSAIDs, and new micronized NSAIDs.

    • UAN: 0530-0000-20-048-L01-P
    • AANP Rx Hours: Coming soon.
  • PRODUCT, DISEASE AWARENESS, MEDICAL INFORMATION PROGRAM*

    Breakfast will be served.

    *This session is not certified for credit.

  • BREAK & EXHIBITS

  • Causalytics – You’re in Pain, and it’s All Your Fault

    Assessment, diagnosis, treatment plan formulation, implementation, and follow-up are processes familiar to clinicians and are the main drivers of safe and effective chronic pain treatment. However, many other things influence our clinical decision-making, including the continuing controversies about the role of opioid analgesics in the management of chronic pain, the “opioid epidemic” our nation faces today, and the fear of regulatory scrutiny just to name a few. Additionally, when formulating decisions about pain treatment, the subjective nature of chronic pain and determining the context of how pain is affecting a person’s life may often be challenging. What we might not be aware of is how other more subtle forces can potentially influence us and have a negative impact on the care we provide for patients—the things that we “bring into the examination room.” This session will focus on how things like precognitive thinking, implicit biases, explicit biases, impressions about patient characteristics and even their demographics may potentially alter our judgment and create disparity. Suggestions will be presented to help recognize and reflect about how we can make sure that the pain care we deliver is not compromised by these things we might not consider, even though they are there.

    • UAN: 0530-0000-20-041-L04-P
    • AANP Rx Hours: 0.10
  • Drugs, Documentation, and DEA: Improving Your Charting of Prescribing Rationale in 2020 and Beyond

    Overlooking the importance of carefully documenting the rationale for the use of a controlled medication can land a prescriber in hot water with their licensing board or the DEA. This course will focus on what it takes to move beyond the problems associated with both EMR and handwritten medical charts, and into the documentation of cogent notes signaling proper patient evaluation, including risk evaluation, rationale for the use of controlled medication, and ongoing encounters with the patient.

    • UAN: 0530-0000-20-027-L03-P
    • AANP Rx Hours: 0.00
  • FACULTY Q&A

  • BREAK & EXHIBITS

  • PRODUCT, DISEASE AWARENESS, MEDICAL INFORMATION PROGRAM*

    Lunch will be served.

    Sponsored by AstraZeneca-Daiichi Sankyo, Inc.

    *This session is not certified for credit.

  • Everybody’s Greasing Up, But Should You Rub It In? A Review of Topical Analgesics and Available Evidence in Clinical Trials

    Topical analgesics are often recommended in clinical practice, but differences between formulations and routes of administration lead to confusion. In addition to commercially prepared topical analgesics, compounded topical analgesics are highly promoted and widely utilized from compounding pharmacies with individualized recipes of multiple combined medications, at substantial cost. To assist providers with tough decisions in this area, the available clinical trials supporting use will be reviewed along with formulations, locations, and doses where their use have been shown to the be most effective. This session will review the role of various topical analgesics as well as explore the rationale for “topical polypharmacy” with compounded drugs.

    • UAN: 0530-0000-20-028-L01-P
    • AANP Rx Hours: Coming soon.
  • BREAK & EXHIBITS

  • PRODUCT, DISEASE AWARENESS, MEDICAL INFORMATION PROGRAM*

    Refreshments will be served.

    *This session is not certified for credit.

  • The Other Opioid Crisis: Heroin and Fentanyl

    There is a significant amount of media, political, and public attention paid to the opioid crisis/opioid epidemic in the United States today. With the seemingly ever-increasing number of opioid-related overdoses and fatalities, there has been a feverish push by stakeholders to diminish the amount of opioids prescribed in order to help stem these worrisome trends. Unfortunately, there may be a lack of focus regarding the true definition and characterization of the opioid epidemic. There may also be a rush to judgment about the role of appropriately prescribed opioid analgesics in the addiction crisis we face today as well. This presentation will discuss the roles and statistics of both prescription and illicit opioids (namely heroin and fentanyl) in today’s “opioid overdose epidemic” with the intention of clarifying important differences and similarities between these competing epidemics including concerns and clinical considerations specific to each of them. Additionally, this program will examine and identify how these medications and drugs share potentially tragic adverse effect profiles in many cases. However, it is important for clinicians to make sure that appropriate chronic pain patients that may be candidates for opioid analgesic therapy aren’t penalized, and still get the treatment that they deserve.

    • UAN: 0530-0000-20-044-L04-P
    • AANP Rx Hours: 0.00
  • Through the Lens of Experts: Meaningful Risk Mitigation and Patient Education

    Those who have been on either side of a courtroom battle on chronic opioid therapy have seen experts and lawyers spend a great deal of time arguing about the extent and nature of risk mitigation and patient education necessary to demonstrate that the prescriber issued a valid controlled substance prescription. The focus of expert testimony is on whether the prescriber engaged in meaningful risk evaluation and monitoring practices, and whether the prescriber individualized medical care for the patient, based on specific history and behaviors as treatment went on. This course will use published medical expert testimony and common expert reports of illegal and insufficient risk mitigation and patient education. The main goal is to facilitate a prescriber's self-audit of risk mitigation practices and to help attendees improve documentation of risk mitigation protocols and patient education efforts. A proactive approach to meaningful risk mitigation is necessary for protecting patient access to quality pain care and creating a framework within which other practitioners may confidently assume care for patients when necessary, and demonstrating appropriate prescribing of chronic opioid therapy.

    • UAN: 0530-0000-20-050-L04-P
    • AANP Rx Hours: 0.00

SPONSORED PROGRAMS

To accompany and enrich your experience at the PAINWeekEnd conference, be sure to attend one or more of the sponsored programs, which are scheduled during breakfast, lunch, and afternoon "Brain Food" time slots in the schedule. There is NO ADDITIONAL CHARGE to attend these program sessions!